| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Medical Research Council (MRC) Molecular Immunopathology Unit, MRC Centre, Hills Road, Cambridge CB2 2QH, UK
2 Division of Transfusion Medicine, Department of Haematology, University of Cambridge, MRC Centre, Hills Road, Cambridge CB2 2QH, UK
3 East Anglian Blood Transfusion Centre, Long Road, Cambridge CB2 2PT, UK
Hepatitis C virus (HCV) is the aetiological agent responsible for most cases of non-A non-B hepatitis. Hepatitis C is a disease of clinical importance because of its high infection rate in blood donors and its persistence as chronic infections which may lead to cirrhosis and hepatocellular carcinoma in the long term. The variability of the HCV genome has posed difficulties in serological detection and vaccine design. The recent advance in phage technology offers a means of cloning human anti-HCV antibodies of a defined specificity that may have potential therapeutic use. We now report the generation of a phage display library using the VH genes of a HCV-infected patient and the VL genes of two non-immune individuals. From this library we were able to obtain specific IgG single-chain Fvs (scFvs) that recognize viral core and envelope proteins by selection on synthetic peptides derived from the core sequence PKARRPEGRTWAQPG and the envelope E2 sequence RPIDDFDQGWGPITY. The specificity of the scFvs was demonstrated by their specific reactions with homologous peptides in ELISA and the specific blocking of scFv binding by homologous peptides, in a dose-dependent manner, in inhibition ELISA. The binding of the anticore 4c2 to homologous peptide was blocked by HCV-positive human sera in an antibody-concentration-dependent manner, suggesting that the scFv recognizes a similar if not identical epitope to those of one or more of the polyclonal antibodies present in the sera.
Present address: The Sanger Centre, Hinxton Hall, Hinxton, Cambridgeshire CB10 1RQ, UK.
Received 26 March 1996;
accepted 4 June 1996.
This article has been cited by other articles:
|
|
 |
|
  V. Barban, S. Fraysse-Corgier, G. Paranhos-Baccala, M. Petit, C. Manin, Y. Berard, A. M. Prince, B. Mandrand, and P. Meulien Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient J. Gen. Virol., February 1, 2000; 81(2): 461 - 469. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z.-X. Zhang, U. Lazdina, M. Chen, D. L. Peterson, and M. Sallberg Characterization of a Monoclonal Antibody and Its Single-Chain Antibody Fragment Recognizing the Nucleoside Triphosphatase/Helicase Domain of the Hepatitis C Virus Nonstructural 3 Protein Clin. Vaccine Immunol., January 1, 2000; 7(1): 58 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. J. Coomber, N. J. Hawkins, M. A. Clark, and R. L. Ward Generation of Anti-p53 Fab Fragments from Individuals with Colorectal Cancer Using Phage Display J. Immunol., August 15, 1999; 163(4): 2276 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Lee, K.-m. Kim, S.-H. Jung, K. J. Lee, E.-C. Choi, Y.-C. Sung, and C.-Y. Kang Identification of a Domain Containing B-Cell Epitopes in Hepatitis C Virus E2 Glycoprotein by Using Mouse Monoclonal Antibodies J. Virol., January 1, 1999; 73(1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
